公司資料
Cocrystal Pharma 股價、新聞與催化劑
- 股票代碼:
- COCP
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.09 USD (-2.68%)
收盤價
最後更新: 2026年8月17日
14.5M USD
市值
股價為何變動
Following the latest company update, “Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors”, COCP closed down 2.68% at $1.09 on Aug 17, 2026. The move occurred in the trading session associated with this company update.
公司概覽
Broad-Spectrum Antiviral Developer
Cocrystal Pharma uses a structure-based drug discovery platform to develop broad-spectrum antiviral medicines targeting conserved regions of viral proteases and polymerases. The strategy is intended to maintain activity across viral variants while minimizing off-target effects.
CDI-988 Norovirus Program
CDI-988 is an oral antiviral candidate for norovirus being evaluated in a Phase 1b human challenge study conducted with Emory University and the University of North Carolina. The trial includes both prevention and treatment cohorts.
Human Challenge Development Model
The controlled human infection study is designed to measure symptom incidence, viral shedding, safety, and pharmacokinetics in a defined setting. This approach can generate early proof-of-concept evidence for both prophylactic and therapeutic use.
Influenza and Coronavirus Pipeline
CC-42344 is a PB2 inhibitor for pandemic and seasonal influenza A. Cocrystal is also developing an inhaled formulation and generating leads for influenza A and B, while CDI-988 may have applications in coronavirus infections.
未來催化劑
- The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
- An additional Phase 2a study of oral CC-42344 in influenza A is planned.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。